NCT02921997View on ClinicalTrials.gov

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

March 28, 2017

Study Completion Date

February 14, 2018

Conditions
Avian InfluenzaH1N1 InfluenzaInfluenza
Interventions
DRUG

AS03

AS03 oil-in-water emulsion adjuvant.

BIOLOGICAL

Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203

Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.

BIOLOGICAL

Monovalent influenza A/H7N9 virus vaccine

Monovalent influenza A/H7N9 virus vaccine.

Trial Locations (1)

37232-0011

Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02921997 - H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses | Biotech Hunter | Biotech Hunter